Onconetix, INC 10-K annual reports

Onconetix, a commercial-stage biotech, is moving forward with a reverse merger to acquire Realbotix, aiming to bolster its financial position and product pipeline while grappling with significant losses and internal control weaknesses.

Onconetix, Inc. reported a substantial net loss of $58.7 million for 2024, a significant working capital deficit, and explicit doubts about its ability to continue as a going concern, while abandoning its ENTADFI commercialization to focus on the Proclarix prostate cancer diagnostic.

Onconetix, Inc. details its capital structure, recent acquisitions, and a strategic shift towards mens health and oncology in its annual 10-K filing.